The company announced corporate developments and financial results for the third quarter of 2017, ended September 30, 2017.
Nov. 15, 2017 12:30 UTC
- The Company and Synbiotics Limited (“Synbiotics”), a group company of Asence Inc, a U.S. incorporated company specializing in supplying pharmaceutical products to international markets, broke ground on its manufacturing facility in India. The Food & Drug Control Administration Gujarat State has approved a 3-year license for the manufacturing of six tests for diagnosing the Zika virus (for export only) and tuberculosis, to be followed by drug-resistant tuberculosis, malaria, dengue, and chikungunya.
- The Company’s products were introduced in several key markets in the Caribbean, including at the 35th annual International Fair of Havana in Cuba, and meetings with the Ministry of Public Health and Social Assistance (SESPAS) of the Dominican Republic.
- The Company is continuing its ground-breaking research applying its proprietary intellectual property in multiplexed molecular diagnostic testing. The Company’s ability to multiplex DNA targets and perform SNP detection has important ramifications for the future growth into the agricultural market, in liquid biopsy for cancer detection, and blood bank screening.
- The Company has been granted ISO 13485:2016 certification following successful completion of an audit of its quality management system to ensure compliance with the newest version of the standard.
Dwight Egan, Co-Diagnostics CEO, remarked, “We are pleased to have completed our initial quarter as a public company. We look forward to growing the Company and driving operational and financial performance for the benefit of our shareholders in the years to come. This quarter’s commercial progress in infectious disease was very exciting. Although not yet reflected in our reported revenues, we are enjoying a strong commercial launch of the CODX Molecular Diagnostics System. To date, the combined populations of the countries in which we have placed systems represent over 50% of the population of the Caribbean Basin. Most of these systems are in prominent reference laboratories that service their respective populations in a “hub and spoke” business model where a single lab collects patient samples from multiple collection points. We expect to have systems placed in a majority of the Caribbean countries by the end of Q1 2018. The Company expects to ship tests to participating labs during Q4 2017 and Q1 2018 that include Zika virus, tuberculosis, hepatitis C, hepatitis B, HIV, and malaria.
In India, during Q4 2017 the company will be delivering its first shipment of tests pursuant to an agreement with MEDCIS Pathlabs India Pvt. Initial shipments under this agreement will be manufactured in the Company’s own ISO 13485 compliant facility in Utah, but will eventually be manufactured and shipped from the new joint venture manufacturing facility currently under construction in India. India is projected to become the largest healthcare market in the world. The Company has taken important steps to capitalize on the burgeoning dynamics of this market. Management believes support in India for the Company’s technology and products is broad-based with qualified prospects coming from across all market segments; ranging from large centralized labs to mid-size private labs and government facilities.
During Q3 2017, the Company also devoted a substantial amount of effort in developing multiplex test opportunities for the agricultural market. Research and development activities are yielding very positive results as the Company’s core intellectual property is enabling materially enhanced multiplexed testing for the agricultural industry. The research and development involved in this initiative appears to be opening up a much larger opportunity to thousands of potential customers with a significant interest in the attributes of the Company’s technology in numerous market segments. In particular the fields of liquid biopsy for cancer detection, blood bank screening and multiplex SNP detection are areas in which we believe the Company’s technology may be applicable.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.
Forward-Looking Statements:
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Risks, uncertainties and other factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission on Annual Report Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
| CO–DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| September 30, 2017 (Unaudited) | December 31, | |||||||
| ASSETS: | ||||||||
| Current Assets | ||||||||
| Cash | $ | 4,625,238 | $ | 998,737 | ||||
| Other receivables | 1,483 | 3,183 | ||||||
| Inventory | 45,340 | -- | ||||||
| Prepaid expenses | 1,240,361 | 206,478 | ||||||
| Total current assets | 5,912,422 | 1,208,398 | ||||||
| Property and equipment, net | 139,749 | 87,429 | ||||||
| Total assets | $ | 6,052,171 | $ | 1,295,827 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT): | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 80,504 | $ | 29,934 | ||||
| Accounts payable (related party) | -- | 75,000 | ||||||
| Accrued expenses | 65,722 | 101,239 | ||||||
| Accrued expenses (related party) | 520,000 | 690,168 | ||||||
| Current notes payable net of $0 and $87,605 discount, respectively | -- | 2,111,895 | ||||||
| Current notes payable (related party) net of $0 and $263 discount, respectively | -- | 837,177 | ||||||
| Deferred revenue | 10,792 | -- | ||||||
| Total current liabilities | 677,018 | 3,845,413 | ||||||
| Long-term Liabilities, net of current portion | ||||||||
| Notes payable | -- | 445,000 | ||||||
| Deferred revenue long-term | 186,144 | -- | ||||||
| Total long-term liabilities | 186,144 | 445,000 | ||||||
| Total liabilities | 863,162 | 4,290,413 | ||||||
| Commitments and contingencies | ||||||||
| STOCKHOLDERS’ EQUITY (DEFICIT): | ||||||||
| Common stock, $.001 par value, 180,000,000 shares authorized; 12,282,975 and 9,882,395 and shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively. | 12,283 | 9,882 | ||||||
| Additional paid-in capital | 16,094,194 | 2,458,744 | ||||||
| Accumulated deficit | (10,917,468 | ) | (5,463,212 | ) | ||||
| Total stockholders’ equity (deficit) | 5,189,009 | (2,994,586 | ) | |||||
| Total liabilities and stockholders’ equity (deficit) | $ | 6,052,171 | $ | 1,295,827 | ||||
| CO–DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | |||||||||||||||||
| For the Three Months | For the Nine Months | ||||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||||
| Revenues: | $ | 2,598 | $ | -- | $ | 5,064 | $ | -- | |||||||||
| Cost of sales | -- | -- | 302 | -- | |||||||||||||
| Gross profit | 2,598 | -- | 4,762 | -- | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Sales and marketing | 117,078 | 28,890 | 306,921 | 76,600 | |||||||||||||
| General and administrative | 1,405,955 | 183,363 | 2,013,213 | 597,505 | |||||||||||||
| Research and development | 272,209 | 172,804 | 721,777 | 539,818 | |||||||||||||
| Depreciation and amortization | 12,416 | 7,295 | 33,228 | 29,466 | |||||||||||||
| Total operating expenses | 1,807,658 | 392,352 | 3,075,139 | 1,243,389 | |||||||||||||
| Loss from operations | (1,805,060 | ) | (392,352 | ) | (3,070,377 | ) | (1,243,389 | ) | |||||||||
| Other expense: | |||||||||||||||||
| Interest expense | (14,801 | ) | (57,598 | ) | (310,233 | ) | (160,052 | ) | |||||||||
| Loss on extinguishment of debt | (2,072,365 | ) | -- | (2,072,365 | ) | -- | |||||||||||
| Loss on disposition of assets | (1,281 | ) | -- | (1,281 | ) | -- | |||||||||||
| Total other expense | (2,088,447 | ) | (57,598 | ) | (2,383,879 | ) | (160,052 | ) | |||||||||
| Loss before income taxes | (3,893,507 | ) | (449,950 | ) | (5,454,256 | ) | (1,403,441 | ) | |||||||||
| Provision for income taxes | -- | -- | -- | -- | |||||||||||||
| Net Loss | $ | (3,893,507 | ) | $ | (449,950 | ) | $ | (5,454,256 | ) | $ | (1,403,441 | ) | |||||
| Basic and diluted income (loss) per common share | $ | (0.33 | ) | $ | (0.05 | ) | $ | (0.53 | ) | $ | (0.14 | ) | |||||
| Weighted average common shares outstanding | 11,751,649 | 9,882,395 | 10,512,327 | 9,882,395 | |||||||||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20171115005524/en/
Contacts
Co-Diagnostics, Inc.
Andrew Benson, 801-438-1036
Investor Relations
investors@codiagnostics.com
or
Lytham Partners
Joe Diaz, Robert Blum, Joe Dorame
602-889-9700
codx@lythampartners.com
Source: Co-Diagnostics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20171115005524/en
